A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in CML Patients with Molecular Evidence of Disease

Protocol No
SWOG-S1712-CML
Principal Investigator
Ehab Atallah
Phase
II
Summary
The purpose of this study is to compare the good and bad effects of adding the study drug ruxolitinib to the usual chemotherapy (called TKI) with the good and bad effects of using TKI alone.
Description
Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: